Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : CMC Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
After 5-Year Delay, Cmc Pharmaceutical Wins FDA Nod for Oral Schizophrenia Drug
Details : Mezofy (aripiprazole) works as a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors, for treating schizophrenia.
Product Name : Mezofy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : CMC Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
